With the potential to unravel genetic mysteries and predict risk of disease, genomics research is taking off in healthcare. However, ethical questions like how and when to alert patients to the information yielded from analysis of their genes will arise as genomic exploration continues.
Feedback from the process of delivering that genetic information will be analyzed to determine a number of things, including the psychological effect it has on patients to the economic strain it has on the healthcare system.
The samples will be pulled from the Partners Biobank, a facility in Cambridge, Mass., where thousands of patient blood samples are stored. Researchers will analyze these samples looking for genetic variants that can be linked to conditions such as mood disorders or hereditary cancers.
The NIH’s eMERGE network, which studies how to effectively combine gene therapy research with EHRs, is also funding eight other facilities across the country to tackle related research. Partners’ Brigham and Women’s Hospital is one of two that will house and coordinate the project’s DNA analysis. The other is Baylor College of Medicine in Houston.
More articles on health IT:
What is the Internet of Things, exactly? 10 quick things to know
Investigation reveals ‘gag clauses’ built into Epic, Cerner, Allscripts EHR contracts impact patient safety
15 hospital, health system chief innovation officers to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
